Friday, March 19, 2010
Designation: Scientist (Bioinformatics)
Qualifications: M.Sc/ PhD
Experience: 0 – 1 yrs
• Candidates will have strong knowledge using–and coding functionality that
interacts with–public nucleotide and protein sequence databases, sequence
alignment software, and related computational genomic resources.
• Strong background in sequence analysis, genome annotation, analysis of
gene or protein expression, protein structure or docking prediction,
comparative genomics is a must. A broad knowledge of statistics and
statistical methods used in analyzing genomics data is preferred.
• C# under the .Net Framework as well as Perl.
• Knowledge of the R\Bioconductor programming language
• Strong background in multi-univariate and Bayesian statistics, and some
experience in machine-learning techniques (SVM, NN).
• We welcome expertise in Python, Bioperl, Ruby, Java, C++/C, and Matlab
• Understanding of scientific workflows, laboratory instrument interactions
and scientific data
• Ability to discuss informatics software specifically, bioinformatics,
chemo informatics,LIMS, SDMS, other Life Science analytical applications, at
varying levels of detail
• Ability to gather market / prospect requirements and scientific use cases
and contribute to effective implementation of scientific use cases in
complex data environments
• Writing research papers, posters, participation in conferences seminars
Note: Application expires on 28th April,2010
Friday, March 12, 2010
These assets include instruments that are key to the Roche NimbleGen microarray workflow, such as the 4-and-12-bay NimbleGen Hybridization Systems.
Roche said that it will transfer the manufacturing capabilities associated with these products to its own in-house facility.
"Acquiring these assets will allow Roche complete control over the production, support, and service of these products to ensure continued timely distribution, full support, and the high level of service our customers have grown to expect from Roche," Roche NimbleGen VP of Marketing Andreas Görtz said in a statement.
NimbleGen originally partnered with BioMicro for custom hybridization for its chips in 2007, before it was acquired by Roche later that year.
Financial terms of the agreement were not released.
Wednesday, March 3, 2010
The firms announced the deal yesterday — several days after reports that Thermo Fisher Scientific had made a $6 billion bid for Millipore.
Under terms of the deal, Darmstadt, Germany's Merck will pay $107 per share for all of Millipore's stock for a total transaction value of roughly $7.2 billion. The deal values Millipore at 4.4 times its 2009 sales of $1.65 billion.
"By combining Millipore's bioscience and bioprocess knowledge with our own expertise in serving pharma customers, we will be able to unlock value in our chemicals business and transform it into a strong growth driver for Merck," Karl-Ludwig Kley, chairman of the executive board of Merck KGaA. "Through this acquisition, we will expand the overall product offering of the Merck Group, using the well-recognized Millipore brand in addition to our own brand."
Merck said that its chemicals business currently generates around 25 percent of its total revenues, but following the acquisition that will increase to 35 percent of total group revenues. Merck, which also has a large pharmaceuticals business, expects the combined business will generate annual cost synergies of around $100 million within three years of the closing of the deal.
Millipore's headquarters will remain in Billerica, Mass., the firms said, and will be combined with Merck's US chemicals headquarters. In addition, Merck said that it intends to "build on Millipore's talented workforce and intends to retain its senior management."
Merck will fund the acquisition with available cash and a term loan provided by Bank of America Merrill Lynch, BNP Paribas, and Commerzbank Aktiengesellschaft. It plans to replace part of the facility through the issuance of bonds.
The boards of directors of both firms have approved the transaction, which will require the approval of Millipore's shareholders. The firms expect to complete the deal in the second half of 2010.
In a research note issued on Monday morning, Thomas Weisel analyst Peter Lawson said that the Merck-Millipore deal "refocuses attention on the potential of industry consolidation."
In early Monday trade on the New York Stock Exchange, shares of Millipore were up 11 percent at $104.88.
Life Science and Informatics
is this a new industry?
or a old wine in a new bottle?
Well Life Sciences and Informatics can be anything form computational biology, all omes and omics, core bioinformatics to curation and literature mining, database creation, in the area of biology, chemistry , bio-chem space.
There are number of companies in India and bangalore is the forefront as a major bio-cluster with 20 to 30 companies in this sphere.
now how good are these companies doing?
how good are they in terms of the international markets and how profitable is their business?
what do they do?
These are some interesting things that could be discussed in this blog page...